Clinical Proteomic Tumor Analysis Consortium Scientific Symposium

The National Cancer Institute’s Office of Cancer Clinical Proteomics Research (OCCPR) and Clinical Proteomic Tumor Analysis Consortium (CPTAC) is pleased to announce the 2019 CPTAC Symposium, which offers an exciting opportunity to learn about the field of cancer proteogenomics and the strides in cancer research made by CPTAC investigators. 

The CPTAC program is a national effort to accelerate the understanding of cancer biology through the application of large-scale proteome and genome analysis, or proteogenomics.  By combining the two fields, CPTAC has been able to broaden our understanding of a cancer’s ‘input codes’ (genes) that help us distinguish tumor types, and their ‘output codes’ (proteins) which are the true and direct site of action of most drugs, to paint a clearer picture of how this information may be exploited therapeutically to improve patient care. This is the next frontier of cancer therapies and CPTAC is on the front lines.

CPTAC has pioneered the integrated proteogenomic analysis of colorectal, breast and ovarian cancer to reveal new insights into these cancer types, such as: identification of proteomic-centric subtypes, prioritization of driver mutations by correlative analysis of copy number alterations and protein abundance, and understanding cancer-relevant pathways through posttranslational modifications.

CPTAC is currently leveraging its investment in cancer proteogenomics by characterizing multiple cancer types, expanding its application through open-source community resources, and accelerating precision oncology by applying proteogenomics to questions of toxicity and resistance in association with clinical trials.